← Back to portfolio Porfolio / DefiniGEN

DefiniGEN

A University of Cambridge supported company whose mission is to provide optimized human cell products to the scientific community.

Company overview

DefiniGEN is a spin-out from the University of Cambridge, creating highly predictive disease cell models for preclinical research and drug development. The process of bringing new drugs to market is arduous, expensive and blighted by a high failure rate. DefiniGEN’s models help the biopharma industry to respond to these challenges, enabling highly relevant information on potential new drug efficacy to be realised in an accelerated manner.

Website
DefiniGEN

Our technology platform harnesses iPSC technology to develop models that are transformational for drug discovery. We have gained significant commercial momentum in recent years, and this investment will be a significant driver of continued growth for DefiniGEN. We’re thrilled to be working with BGF, who understand the complex issues that we are addressing and are committed to helping us accelerate the next phase of growth.

Dr Marcus Yeo , CEO

Company information

Head office
  • Cambridge
CEO
  • Dr. Marcus Yeo
Chair
BGF office
Investment date
  • Nov 2020
Total BGF investment
  • £2m